HIV-Associated “Double-Hit” Lymphoma of the Tonsil: A First Reported Case

Hinkle, Chad; Makar, Gabriel; Brody, Joshua; Ahmad, Nadir; Zhu, Gord Guo

doi:10.1007/s12105-020-01135-1

Cited by 4 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these genetic abnormalities have been already reported in HIV‐infected patients, to the best of our knowledge this is the first systematic study by FISH in a large series of HIV‐associated lymphoma, leading to understand the real prevalence of HGBL‐DH/TH and BL‐like with 11q aberration in the HIV‐setting. 16 , 17 , 18 , 19 Importantly, we studied the prognostic impact of COO subtypes and of some phenotypic markers, including MYC, BCL2 and DE, in the subset of patients with DLBCL treated with RCHOP.…”

Section: Discussionmentioning

confidence: 99%

Genetic and phenotypic characterisation of HIV‐associated aggressive B‐cell non‐Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications

et al. 2022

View full text Add to dashboard Cite

The frequency of aggressive subtypes of B‐cell non‐Hodgkin lymphoma (B‐NHL), such as high‐grade B‐cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL‐DH/TH) or Burkitt‐like lymphoma (BL) with 11q aberration, is not well known in the HIV setting. We aimed to characterise HIV‐associated aggressive B‐NHL according to the 2017 WHO criteria, and to identify genotypic and phenotypic features with prognostic impact. Seventy‐five HIV‐associated aggressive B‐NHL were studied by immunohistochemistry (CD10, BCL2, BCL6, MUM1, MYC, and CD30), EBV‐encoded RNAs (EBERs), and fluorescence in situ hybridisation (FISH) to evaluate the status of the MYC, BCL2, and BCL6 genes and chromosome 11q. The 2017 WHO classification criteria and the Hans algorithm, for the cell‐of‐origin classification of diffuse large B‐cell lymphomas (DLBCL), were applied. In DLBCL cases, the frequencies of MYC and BCL6 rearrangements (14.9 and 27.7%, respectively) were similar to those described in HIV‐negative patients, but BCL2 rearrangements were infrequent (4.3%). MYC expression was identified in 23.4% of DLBCL cases, and coexpression of MYC and BCL2 in 13.0%, which was associated with a worse prognosis. As for BL cases, the expression of MUM1 (30.4%) conferred a worse prognosis. Finally, the prevalence of HGBL‐DH/TH and BL‐like with 11q aberration are reported in the HIV setting. The phenotypic and genotypic characteristics of HIV‐associated aggressive B‐NHL are similar to those of the general population, except for the low frequency of BCL2 rearrangements in DLBCL. MYC and BCL2 coexpression in DLBCL, and MUM‐1 expression in BL, have a negative prognostic impact on HIV‐infected individuals.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic and phenotypic characterisation of HIV‐associated aggressive B‐cell non‐Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The etiology and risk factors for the development of lymphosarcoma are gene rearrangement (Nachmias et al, 2019), chromosome translocation (Chiu and Blair, 2009), and viruses such as Epstein-Barr virus (Muncunill et al, 2019), human immunodeficiency virus (Song et al, 2020;Hinkle et al, 2020), hepatitis B/C virus (Zhu et al, 2019;Kim et al, 2020), helicobacter pylori (Smedby and Ponzoni, 2017) and human herpes virus (Cho et al, 2015) infection.…”

Section: Introductionmentioning

confidence: 99%

Lymphosarcoma Incidence in Kazakhstan: A Retrospective Survey (2010-2019)

Bayembaev

Rakhimzhanova

Dautov

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: The aim is to study the trends of lymphosarcoma incidence in the regional context in Kazakhstan. Methods: The retrospective study was done using descriptive method of oncoepidemiology. The extensive, crude and age-specific incidence rates are determined according to the generally accepted methodology used in statistics. The data were used to calculate the average percentage change (APС) using the Joinpoint regression analysis to determine the trend over the study period. Results: 3,987 new cases of lymphosarcoma were registered in the country (50.7% in men, 49.3% in women). During the studied years the average age of patients was 54.2±0.8 years. The highest incidence rates per 100,000 in the entire population were found in the age groups 65-69 years (10.4±0.6), 70-74 years (10.7±0.8), and 75-79 years (10.3±0.8). The highest tendency to increase in age-related incidence rates was at the age over 85 (APC=+8.26) and to decrease at the age under 30 (APC=−6.17). The average annual standardized incidence rate was 2.3 per 100,000, and in dynamics tended to increase (APC=+1.43). It was found that the downward trend was observed in five regions (Akmola, Atyrau, Karaganda, North and South Kazakhstan), and the most pronounced decline was in the Karaganda (APC=−3.61) and South Kazakhstan (APC=−2.93) regions. When compiling thematic maps, incidence rates were determined based on standardized indicators: low – up to 1.97, average – from 1.97 to 2.60, high – above 2.60 per 100,000 for both sexes. Conclusion: Trends in the incidence of lymphosarcoma in Kazakhstan are growing and have geographical variability, and a high incidence is observed in the eastern and northern regions of the country. Sex differences have been established the incidence in men is higher than in female population, but the rate of increase in the incidence in women is more pronounced.

show abstract